Skip to main content

Table 4 Ongoing studies of immune checkpoint inhibitors in ovarian cancer

From: The role of immune checkpoint inhibition in the treatment of ovarian cancer

Phase

Trial number

Trial

Disease status

Immunotherapy agent(s)

Concurrent therapy

3

NCT02580058

A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)

recurrent platinum resistant

Avelumab

Liposomal Doxorubicin

3

NCT02718417

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

primary

Avelumab

Carboplatin Paclitaxel

3

ENGOT-ov29-GCIG

A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab

recurrent platinum sensitive

Atezolizumab

Carboplatin-based chemotherapy Bevacizumab

2

NCT02440425

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

recurrent platinum resistant

Pembrolizumab

Dose Dense Paclitaxel

2

NCT02498600

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

recurrent platinum sensitive/resistant

Nivolumab +/- Ipilimumab

 

2

NCT02520154

Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer

primary

Pembrolizumab

Carboplatin Paclitaxel

2

NCT02659384

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

recurrent platinum resistant

Atezolizumab

Bevacizumab Acetylsalicylic Acid

2

NCT02674061

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

recurrent platinum sensitive/resistant

Pembrolizumab

 

2

NCT02764333

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

recurrent platinum resistant

Durvalumab

TPIV200/huFR-1 (anti-folate receptor vaccine)

2

NCT02766582

Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer

suboptimally cytoreduced primary

Pembrolizumab

Carboplatin Paclitaxel

1/2

NCT02431559

A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated

recurrent platinum resistant

Durvalumab

Motolimod Pegylated Liposomal Doxorubicin

1/2

NCT02484404

Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer

recurrent platinum sensitive/resistant

Durvalumab

Olaparib or Cediranib

1/2

NCT02485990

Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

recurrent or persistent

Tremelimumab

Olaparib

1/2

NCT02571725

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

BRCA-deficient recurrent platinum sensitive/resistant

Tremelimumab

Olaparib

1/2

NCT02657889

Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162)

recurrent platinum resistant

Pembrolizumab

Niraparib

1/2

NCT02726997

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer

primary

Durvalumab

Carboplatin Paclitaxel

1

NCT02737787

A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

≥2nd remission

Nivolumab

WT1 vaccine

0

NCT02728830

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

primary

Pembrolizumab

Â